

United States Senate

WASHINGTON, DC 20510

January 15, 2017

Hon. Tom Price
Member of Congress
1211 Longworth House Office Building
Washington, DC 20515

Dear Congressman Price:

Recent news reports have raised concerns regarding your investments in the Australian biomedical firm Innate Immunotherapeutics Limited ("Innate Immuno"). Prior to your nomination hearing as Secretary of the Department of Health and Human Services, we ask that you provide additional information on these investments.

The Wall Street Journal reports that, over the last four years, you have actively traded in health-related stocks, while you were simultaneously drafting and advancing legislation that could affect the performance of these stocks. In August of 2016, you purchased between \$50,000 and \$100,000 worth of stock in Innate Immuno. The unique circumstances surrounding this transaction merit further inquiry.

First, you made this purchase just two days after your colleague Congressman Chris Collins made a large purchase valued between \$500,000 and \$1 million. Congressman Collins, who is also a member of the President-elect Trump's transition team, serves on Innate Immuno's board and is the company's largest shareholder.

Second, the transaction appears to be out of the ordinary based on your trading history. For example, your purchase of Innate Immuno shares in August 2016 appears to be the largest purchase of any individual stock you made in at least three years. And while you do not appear to routinely participate in private placements, according to press reports, you and Representative Collins both made the August 2016 stock purchases through a private placement offering, which was not widely available to the public.

Finally, you appear to have made a significant profit on the investment in Innate Immuno, despite holding many of your Innate Immuno shares for less than six months. Innate Immuno's share price has appreciated more than 400% in recent months, and your recent financial disclosure filing with the Office of Government Ethics indicates you reported capital gains and dividends suggesting you profited between \$50,001 and \$100,000 from this transaction.

Given the unusual nature of these trades and your position of influence as chair of the House Budget Committee at the time of these trades, it is of utmost importance that you provide answers to our questions as you are being considered for the Administration's top health care post. Therefore, we respectfully ask that you provide answers to our questions prior to your confirmation hearing.

1. Are you responsible for the Innate Immuno trades made in your name, or was another party responsible for one or more of the Innate Immuno transactions you reported in your financial disclosure forms?
2. How did you first become aware of Innate Immuno? Did you discuss or in any other way communicate with Congressman Chris Collins, even informally, about Innate Immuno prior to your decision to invest in the company? Did any information provided by Congressman Collins lead or contribute to your decision to become a shareholder of Innate Immuno?
3. Following your initial decision to acquire an interest in Innate Immuno, did you discuss or in any other way communicate with Congressman Collins about Innate Immuno? If so, when and where did the communication take place? Please provide a description of the communications.
4. Were any communications with Congressman Collins regarding Innate Immuno in written or electronic form, including but not limited to email or text message? If so, please provide copies of any such communications.
5. If information regarding Innate Immuno was provided by Congressman Collins, in your view, was that information provided to you in the course of your official duties as a Member of Congress or in a non-official capacity?
6. Please provide any written or electronic information you obtained from any source regarding Innate Immuno, including but not limited to offering memoranda, prospectuses, or financial statements. When did you acquire such documents and what were the sources of the documents?
7. With respect to the transaction on August 31, 2016, why did you decide to significantly increase your holdings in Innate Immuno?
8. At any time, did you acquire an interest in Innate Immuno through a private placement or other private transaction? If so, when did the transaction take place? What price did you pay? Did the price represent a discount to the value on the public market? If the shares were sold through a private placement, how did you become aware of the private placement? How many other individuals participated in the private placement?
9. Were you in possession of any non-public information that would reasonably be expected to be relevant to an Innate Immuno investor on the dates of any of your trades in the stock? If so, how did you come into possession of this information?


10. As a Member of Congress, it would be expected that in the course of your official duties, you may be presented with matters that could potentially impact Innate Immuno. Please describe the steps you took, if any, to mitigate any conflict of interest or appearance of conflict of interest resulting from your investments in Innate Immuno.
11. Have you made any transactions involving Innate Immuno stock since August 31, 2016? If so, please provide the date of the transaction, number of shares traded, price received, and if a sale, the amount of any capital gain realized and the nature of the sale (private sale, sale on public market, etc). In addition, your financial disclosure indicates you received dividends from Innate Immuno. If so, please provide the date and amount of any dividend you received.

We look forward to your prompt response to this inquiry.


Sincerely,



Al Franken
United States Senator



Tammy Baldwin
United States Senator



Elizabeth Warren
United States Senator